Target Name: ZMYND11
NCBI ID: G10771
Other Name(s): ZMY11_HUMAN | zinc finger MYND-type containing 11 | BRAM1 | adenovirus 5 E1A-binding protein | ZMYND11 variant 2 | Zinc finger, MYND domain containing 11 | OTTHUMP00000197455 | MGC111056 | Zinc finger MYND-type containing 11, transcript variant 1 | Zinc finger MYND domain-containing protein 11 | BS69 | OTTHUMP00000018937 | Zinc finger MYND-type containing 11, transcript variant 2 | OTTHUMP00000018935 | bone morphogenetic protein receptor-associated molecule 1 | Bone morphogenetic protein receptor-associated molecule 1 | OTTHUMP00000197456 | RP11-486H9.1 | Adenovirus 5 E1A binding protein | Adenovirus 5 E1A-binding protein | Zinc finger MYND domain-containing protein 11 (isoform b) | Protein BS69 | MRD30 | OTTHUMP00000018936 | Zinc finger MYND domain-containing protein 11 (isoform a) | ZMYND11 variant 1

Unlocking The Potential of ZMYND11: A Protein Target for Drug Development

ZMYND11 (ZMY11_HUMAN), a protein that belongs to the ZMYND family, has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and function have made it an attractive target for researchers to study and develop new treatments.

The ZMYND family is a protein family that contains four structurally similar but functionally distinct proteins: ZMYND1, ZMYND2, ZMYND3, and ZMYND4. These proteins are characterized by their unique N-terminal and C-terminal regions, which contain a variable number of domains and a unique fold. ZMYND11 is a member of the ZMYND family, and its unique structure has made it an interesting candidate for drug development.

One of the key features of ZMYND11 is its unique folds, which are responsible for its unique structure and function. ZMYND11 has a characteristic N-terminal region that contains a nucleotide-binding oligomerization domain (NBO), which is responsible for the protein's ability to interact with nucleotides. Additionally, ZMYND11 has a distinct C-terminal region that contains a unique protein-coding domain that is not found in any other protein in the ZMYND family.

The unique folds of ZMYND11 are what make it an attractive candidate for drug development. The NBO domain is known to be involved in various cellular processes, including DNA replication, transcription, and RNA processing. This domain has been shown to be involved in the regulation of gene expression and has been linked to various diseases, including cancer. Additionally, the C-terminal region of ZMYND11 contains a unique protein-coding domain that has not been studied extensively, but is known to be involved in the regulation of cellular processes such as cell adhesion and migration.

ZMYND11 has also been shown to be involved in various signaling pathways, including the TGF-β pathway. TGF-β is a well-known signaling pathway that is involved in the regulation of cellular processes such as cell growth, differentiation, and inflammation. ZMYND11 has been shown to be a positive regulator of TGF-β signaling and has been linked to the development of various diseases, including cancer.

In addition to its potential role in disease, ZMYND11 has also been shown to be a potential drug target. The NBO domain of ZMYND11 has been shown to be involved in the regulation of various cellular processes, including cell signaling and DNA replication. This suggests that targeting this domain may have potential benefits for treating various diseases. Additionally, the unique C-terminal region of ZMYND11 that is not found in other proteins in the ZMYND family may be a potential drug target for its unique functions.

In conclusion, ZMYND11 is a protein that has unique structure and function, making it an attractive candidate for drug development. Its unique N-terminal and C-terminal regions, as well as its involvement in various signaling pathways, make it a promising target for the development of new treatments for various diseases. Further research is needed to fully understand the unique functions of ZMYND11 and its potential as a drug target.

Protein Name: Zinc Finger MYND-type Containing 11

Functions: Chromatin reader that specifically recognizes and binds histone H3.3 trimethylated at 'Lys-36' (H3.3K36me3) and regulates RNA polymerase II elongation. Does not bind other histone H3 subtypes (H3.1 or H3.2) (By similarity). Colocalizes with highly expressed genes and functions as a transcription corepressor by modulating RNA polymerase II at the elongation stage. Binds non-specifically to dsDNA (PubMed:24675531). Acts as a tumor-suppressor by repressing a transcriptional program essential for tumor cell growth

More Common Targets

ZMYND12 | ZMYND15 | ZMYND19 | ZMYND8 | ZNF10 | ZNF100 | ZNF101 | ZNF106 | ZNF107 | ZNF112 | ZNF114 | ZNF117 | ZNF12 | ZNF121 | ZNF124 | ZNF131 | ZNF132 | ZNF133 | ZNF134 | ZNF135 | ZNF136 | ZNF137P | ZNF138 | ZNF14 | ZNF140 | ZNF141 | ZNF142 | ZNF143 | ZNF146 | ZNF148 | ZNF154 | ZNF155 | ZNF157 | ZNF16 | ZNF160 | ZNF165 | ZNF169 | ZNF17 | ZNF174 | ZNF175 | ZNF177 | ZNF18 | ZNF180 | ZNF181 | ZNF182 | ZNF184 | ZNF185 | ZNF189 | ZNF19 | ZNF195 | ZNF197 | ZNF2 | ZNF20 | ZNF200 | ZNF202 | ZNF204P | ZNF205 | ZNF205-AS1 | ZNF207 | ZNF208 | ZNF209P | ZNF211 | ZNF212 | ZNF213 | ZNF213-AS1 | ZNF214 | ZNF215 | ZNF217 | ZNF219 | ZNF22 | ZNF22-AS1 | ZNF221 | ZNF222 | ZNF223 | ZNF224 | ZNF225 | ZNF225-AS1 | ZNF226 | ZNF227 | ZNF229 | ZNF23 | ZNF230 | ZNF232 | ZNF232-AS1 | ZNF233 | ZNF234 | ZNF235 | ZNF236 | ZNF236-DT | ZNF239 | ZNF24 | ZNF248 | ZNF25 | ZNF250 | ZNF251 | ZNF252P | ZNF252P-AS1 | ZNF253 | ZNF254 | ZNF256